文献速递泌尿生殖腹部MR

前列腺癌MRI自主AI:迈向临床应用的路径

Autonomous AI in prostate cancer: the road ahead towards clinical implementation.
PubMed 文献 · Abdom Radiol (NY) · 2026-08-08

本叙述性综述探讨自主人工智能在前列腺MRI中检测临床显著性前列腺癌(csPCa)的临床应用障碍。文章聚焦证据基础局限、安全性与缓解策略、患者与放射科医生接受度三大领域。结论指出需多中心前瞻性试验、部署监测机制及提升透明度与教育以推动负责任实施。

要点

  • 自主AI检测csPCa诊断效能与放射科医生相当,但尚未进入临床实践。
  • 阅片时需关注AI训练数据与当前扫描不匹配的潜在错误风险。
  • 患者和放射科医生对自主AI接受度有限,透明度和教育可改善此状况。

核心结论

  • 自主AI在前列腺MRI检测csPCa方面具备与放射科医生相当的诊断效能,但临床实施仍面临证据、安全性和接受度等多重障碍。
  • 需要来自大型多中心前瞻性试验的证据和反映临床决策后果的评估框架来支持自主AI的部署。

研究设计与样本

  • 本文为叙述性综述,无原始样本量、中心数、设备型号或参考标准的系统报告。
  • 检索范围涵盖自主AI检测csPCa的技术与社会障碍相关文献,未报告具体数据库、检索式或纳入文献数量。

临床应用与阅片要点

  • 在日常阅片中引入自主AI前,应关注训练数据与当前扫描之间不匹配的监测与处理机制。
  • 需对患者和放射科医生进行针对性教育以提高对自主AI的接受度,并明确医疗法律责任指南。

局限性

  • 当前证据基础存在局限,缺乏大型多中心前瞻性试验支撑自主AI的临床推广。
  • 患者和放射科医生对自主AI的接受度有限,构成部署的社会性障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Artificial Intelligence (AI) for detecting clinically significant prostate cancer (csPCa) on MRI has achieved diagnostic performance comparable to that of radiologists. By autonomously interpreting examinations, AI could improve workflow efficiency and help address increasing imaging demands and radiologist shortages. Despite this promise, autonomous AI has not been implemented in clinical practice. This narrative review explores remaining technical and societal barriers to deploying autonomous csPCa detection. We focus on three key domains: limitations in the current evidence base, safety issues and mitigation strategies, and the perspectives of patients and radiologists. Our findings highlight the need for evidence from large, multicenter, prospective trials and evaluation frameworks that reflect the consequences of clinical decision-making, as well as further exploration of safeguards to monitor and address mismatches between training data and incoming scans during deployment. Moreover, patients and radiologists show limited acceptance of autonomous AI, although this may improve with greater transparency, targeted education, and clearer guidelines on medico-legal responsibilities. Addressing these challenges is essential to the responsible deployment of autonomous AI and to realizing its efficiency gains in clinical practice.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Koopmans, Vega Lara, Roest, et al. Autonomous AI in prostate cancer: the road ahead towards clinical implementation. Abdom Radiol (NY). 2026. PMID: 42570088. doi:10.1007/s00261-026-05711-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。